Summary:
Revvity, Inc. has launched the IDS i20, a fully automated, high-throughput platform for chemiluminescence immunoassays (ChLIA), enabling labs to consolidate specialty tests with greater efficiency and reliability.
Takeaways:
- High Capacity & Speed: The IDS i20 can run up to 140 tests per hour and process 20 analytes simultaneously across six diagnostic specialties.
- Automation Upgrade: It transitions labs from manual/semi-automated systems to fully automated workflows, enhancing efficiency.
- Advanced Software: The platform features modern, user-friendly software with continuous loading and integrated reagent cooling for uninterrupted operation.
Revvity, Inc., has announced the launch of its new IDS i20 analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings.
ChLIA Platform Allows Simultaneous Running of 20 Analytes
The highly versatile IDS i20 instrument allows users to simultaneously run 20 analytes from six diagnostic specialties on a single device. These specialties include endocrinology, allergy, autoimmune and infectious disease testing, testing for Alzheimer’s disease and therapeutic drug monitoring. While specialty assays in these diagnostic areas tend to be processed manually or with semi-automated, low-throughput analyzers, the IDS i20 platform offers labs a new means of more flexible, fully automated ChLIA processing.
“With the IDS i20 instrument, we’re able to support our customers making the transition from manual and semi-automated processing to a fully automated solution for enhanced immunodiagnostics workflows,” explains Dr. Bianca Huth, chief technical officer of EUROIMMUN. “Having been built on decades of experience in laboratory automation, the IDS i20 platform is intended to meet or exceed laboratories’ demands for reliability, versatility and usability.”
With the ability to process up to 140 tests per hour (assay dependent), the IDS i20 instrument is the latest addition to the well-established IDS i-device series, built on more than 50 years of experience in medical device design and innovation.
IDS i20 Features State-of-the-Art Software
The IDS i20 platform features new state-of-the-art software offering a high degree of adaptability and scalability, along with a superior graphical user interface that meets the latest standards of ergonomics, usability and cybersecurity. Continuous loading of samples and reagents as well as the integrated cooling of ready-to-use reagent cartridges allow for non-stop operation of the system – maximizing efficiency and minimizing hands-on time.
For In Vitro Diagnostic Use. Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability.
Featured Image: IDS i20 analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. Image: Revvity
